Floatz logo

METHOTREXATE

Recurrent Adult Acute Lymphoblastic Leukemia

Shanxi Bethune HospitalSmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Recurrent Adult Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Inno-206
Chen Suning
Phase 4BBB
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BBB
(+)-VINCRISTINE
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BBB
ETOPOSIDE
Shanxi Bethune Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →